An international consortium, led in part by clinicians and researchers from The University of Texas MD Anderson Cancer Center, has published a series of best-practice recommendations for conducting clinical trials for neoadjuvant, or pre-surgical, therapies in patients with locally advanced melanoma.
The report, published in Lancet Oncology, provides recommendations for clinical trial design, including patient inclusion criteria...
The Therapeutics Discovery division at MD Anderson Cancer Center has advanced a new small-molecule inhibitor of cancer metabolism to Phase...
Through in-depth retrospective analysis of data from more than 36,000 patients, a new study led by researchers at The University of Texas...
Neoadjuvant therapy is treatment, such as chemotherapy or radiation, given before a patient has surgery. This approach is used in many cancer types to treat microscopic disease that has spread to other organs (micro-metastases) or shrink the primary tumor before proceeding with surgical removal. However, this approach has not been widely adopted in the community when treating patients with pancreatic cancer.
Over the past two decades...
MD Anderson’s proteomics platform provides a valuable institutional resource, complete with state-of-the-art instruments and specialized expertise...
Chronic lymphocytic leukemia (CLL), which originates in white blood cells known as lymphocytes, is the most common form of leukemia in adults...
MD Anderson Cancer Center researchers, together with collaborators from Mozambique, Brazil and the U.S., have been awarded a $5.1 million...
Receiving a cancer diagnosis is a life-changing event, and the path through treatment can be among the hardest things a person goes through...